Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma: Frequency and Duration of Detection of Daratumumab and Elotuzumab.

Conclusions: When distinguishable from M-protein, t-mAbs are detectable in 93% of treated patients as soon as 7 days after the initial dose and are consistently observed throughout induction therapy, warranting increased monitoring and careful interpretation of SPE/IF.
PMID: 29901687 [PubMed - as supplied by publisher]

Source: American Journal of Clinical Pathology - June 13, 2018 Category: Pathology Authors: Tang F, Malek E, Math S, Schmotzer CL, Beck RC Tags: Am J Clin Pathol Source Type: research